Malignant myeloid blast cells may occasionally form a solid mass in tissues outside the haemopoietic system. These tumours are known as chloromas or granulocytic sarcomas. Chloromas occur most commonly in the context of acute myelogenous leukaemia but, rarely, they occur in the absence of other haematological disease, and may be misdiagnosed as lymphoma. A case of a previously well 35-year-old woman presenting with rapidly progressive triplegia caused by a paraspinal and extradural cervical chloroma with no evidence of bone marrow or other haematological involvement is described. Few cases of spinal cord compression caused by chloroma in otherwise healthy patients have been reported. Morphological features of myeloid differentiation, histochemistry and immunohistochemistry, may all aid in rapid diagnosis and allow early and appropriate therapy.

Download full-text PDF

Source

Publication Analysis

Top Keywords

spinal chloroma
4
chloroma presenting
4
presenting triplegia
4
triplegia aleukaemic
4
aleukaemic patient
4
patient malignant
4
malignant myeloid
4
myeloid blast
4
blast cells
4
cells occasionally
4

Similar Publications

A rare case of spinal myeloid sarcoma.

Surg Neurol Int

November 2024

Limburg Clinical Research Centre (LCRC), University of Hasselt, Hasselt, Belgium.

Background: Myeloid sarcoma (MS), a rare extramedullary tumor composed of myeloid blast cells, is classified by the World Health Organization as a subtype of acute myeloid leukemia (AML). Isolated, primary, or nonleukemic MS has an incidence of 2/1,000,000 adults and constitutes only 0.7% of all AML cases.

View Article and Find Full Text PDF

Background: Acute promyelocytic leukemia (APL) is rarely caused by the fusion gene. While APL patients with fusion commonly exhibit diverse hematologic symptoms, the presentation of myeloid sarcoma (MS) as an initial manifestation is infrequent.

Case Presentation: A 61-year-old patient was referred to our hospital with 6-month history of low back pain and difficulty walking.

View Article and Find Full Text PDF

Background: The treatment of myeloid sarcoma (MS) is challenging and has not markedly improved patient prognosis. The introduction of venetoclax (VEN) has changed the treatment of MS, and venetoclax-based therapy has been described as very promising in several case reports.

Methods: In this retrospective study, we analyzed the treatment outcomes of 14 patients with MS treated with venetoclax-based therapy at The First Affiliated Hospital of Xiamen University from January 2020 to October 2023 RESULTS: The cohort consisted of 7 (50%) women and 7 (50%) men with an average age of 37.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!